Rationale: The D6 chemokine receptor can bind and scavenge several chemokines, including the T-helper 2 (Th2)-associated chemokines CCL17 and CCL22. Although D6 is constitutively expressed in the lung, its pulmonary function is unknown. Objectives: This study tested whether D6 regulates pulmonary chemokine levels, inflammation, or airway responsiveness during allergen-induced airway disease. Methods: D6-deficient and genetically matched C57BL/6 mice were sensitized and challenged with ovalbumin. ELISA and flow cytometry were used to measure levels of cytokines and leukocytes, respectively. Mechanical ventilation was used to measure airway reactivity. Results: The ability of D6 to diminish chemokine levels in the lung was chemokine concentration dependent. CCL17 and CCL22 were abundant in the airway, and their levels were attenuated by D6 when they were within a defined concentration range. By contrast, airway concentrations of CCL3, CCL5, and CCL11 were low and unaffected by D6. Allergen-challenged D6-deficient mice had more dendritic cells, T cells, and eosinophils in the lung parenchyma and more eosinophils in the airway than similarly challenged C57BL/6 mice. By contrast, D6-deficient mice had reduced airway responses to methacholine compared with C57BL/6 mice. Thus, D6 has opposing effects on inflammation and airway reactivity. Conclusions: The ability of D6 to scavenge chemokines in the lung is dependent on chemokine concentration. The absence of D6 increases inflammation, but reduces airway reactivity. These findings suggest that inhibiting D6 function might be a novel means to attenuate airway responses in individuals with allergic asthma.Keywords: chemokines; lung; D6; allergic; transforming growth factor- Allergic asthma is a disease characterized by pulmonary inflammation and reversible airflow obstruction. In allergic asthma, T-helper 2 (Th2) cells recognizing common airborne antigens produce the cytokines IL-4, IL-5, and IL-13, which can account for virtually all of the manifestations of asthma, including eosinophil mobilization and airway remodeling (1). In principle, an effective therapy for asthma would be to inhibit the development of such allergen-specific Th2 cells. However, individuals that present with asthma have already developed Th2 responses to aeroaller- The D6 chemokine receptor can bind and scavenge several chemokines, including the T-helper 2-associated chemokines CCL17 and CCL22. Although D6 is constitutively expressed in the lung, its function is unknown.
What This Study Adds to the FieldThe absence of D6 increases airway inflammation, but reduces airway reactivity. Inhibiting D6 might attenuate airway responses in individuals with asthma.